Breaking News Instant updates and real-time market news.

BIIB

Biogen

$275.41

-2.46 (-0.89%)

, SRPT

Sarepta

$29.68

-0.51 (-1.69%)

04:55
03/24/17
03/24
04:55
03/24/17
04:55

Muscular Dystrophy Association to hold a conference

2017 MDA Scientific Conference is being held in Arlington, VA on March 19-22.

BIIB

Biogen

$275.41

-2.46 (-0.89%)

SRPT

Sarepta

$29.68

-0.51 (-1.69%)

FOLD

Amicus

$7.14

0.07 (0.99%)

CATB

Catabasis Pharmaceuticals

$1.32

-0.085 (-6.05%)

BIIB Biogen
$275.41

-2.46 (-0.89%)

03/17/17
GSCO
03/17/17
NO CHANGE
Target $108
GSCO
Buy
AveXis price target raised to $108 on higher confidence in AVXS-101 at Goldman
After AveXis (AVXS) reported results for its Phase 1 study of AVXS-101 in spinal muscular atrophy, Goldman Sachs analyst Salveen Richter said data for the treatment continues to impress and increased his probability of success for the drug to 85% from 65% previously. The analyst, who views AVXS-101 as a key competitive threat to Biogen (BIIB) and Ionis' (IONS) Spinraza as the potential first-line treatment for SMA, raised his price target on AveXis to $108 from $91 and keeps a Buy rating on the shares.
03/21/17
GSCO
03/21/17
NO CHANGE
Target $282
GSCO
Neutral
Biogen IPR win removes worst-case scenario for Tecfidera, says Goldman
Goldman Sachs analyst Terence Flynn said the USPTO's favorable decision in Kyle Bass' patent challenge to Biogen's Tecfidera removes a worst-case scenario, but notes there is still an outstanding interference proceeding between the company and competitor Forward Pharma regarding the MS drug. Flynn, who projects Tecfidera maintains U.S. exclusivity until 2028 while assuming that Biogen will pays a 10% royalty to Forward Pharma, keeps a Neutral rating and $282 price target on Biogen shares.
03/21/17
RAJA
03/21/17
NO CHANGE
RAJA
Strong Buy
Biogen patent ruling worth $13-$25 per share, says Raymond James
Most investors were expecting a loss for Biogen in today's s Tecfidera patent ruling, Raymond James analyst Christopher Raymond tells investors in an intraday research note. Today's decision means Tecfidera's exclusivity stretches to at least 2025 and possibly to 2028, which the analyst pegs at being worth $13-$25 per share. He recommends buying the stock "before the market figures this out." Raymond has a Strong Buy rating on Biogen. The stock is up $4.16 to $278.96 in midday trading.
03/21/17
JEFF
03/21/17
NO CHANGE
Target $289
JEFF
Buy
Jefferies views Biogen patent ruling as in-line with expectations
Jefferies analyst Brian Abrahams believed with a 70% likelihood that Biogen would prevail in the inter partes review against Hayman Capital's Kyle Bass. Thus, he views patent decision as in-line with expectations. Raymond James analyst Christopher Raymond, on the other hand, said in an intraday research note that he believes most investors were expecting Biogen to lose the patent case. Abrahams thinks the outcome today is a de-risking event for Biogen and removes one of the two possibilities of an unlikely worst-case scenario, with the other being that both patents are debunked in the interference. The analyst has Hold rating on Biogen with a $289 price target.
SRPT Sarepta
$29.68

-0.51 (-1.69%)

03/02/17
03/02/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exxon Mobil (XOM) upgraded to Neutral from Underperform at Credit Suisse with analyst Edward Westlake saying that after underperformance versus the S&P, the stock has option value. The analyst also raised his price target on the shares to $83 from $78. 2. RBS (RBS) upgraded to Buy from Hold at Berenberg. 3. Windstream (WIN) upgraded to Hold from Underperform at Jefferies with analyst Scott Goldman saying he sees less risk to estimates following management's 2017 guidance. The analyst upped his price target for the shares to $7.50 from $6. 4. Sarepta (SRPT) upgraded to Outperform from Market Perform at Leerink with analyst Joseph Schwartz saying the stock now reflects "reasonable expectations" for the Exondys launch. Management's new revenue guidance looks "highly conservative," Schwartz tells investors in a research note. The analyst believes share upside could come from Exondys 51 approval in Europe and/or successful development of follow-on antisense candidates. He raised his price target for Sarepta shares to $47 from $27. 5. Estee Lauder (EL) upgraded to Overweight from Neutral at Piper Jaffray with analyst Stephanie Wissink saying the growth is de-risked following the guidance reset. The analyst is "bullish" on the prospects for double digit earnings growth for investors that can look into FY18. She raised her price target for the shares to $95 from $81. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/10/17
COWN
03/10/17
NO CHANGE
Target $62
COWN
Outperform
Cowen sees coverage re-evaluations as positive for Sarepta
Cowen analyst Ritu Baral believes payors are still actively evaluating and re-evaluating coverage of Sarepta Therapeutics' Exondys 51. It appears that Anthem (ANTM), after an initial denial of coverage, has re-evaluated its decision on Exondys, Baral tells investors in a research note. She notes, though, that coverage discussions appear to be ongoing and amenable patients are still experiencing denials. The analyst sees the re-evaluations of coverage as positive for Sarepta. Baral has an Outperform rating on the shares with a $62 price target.
03/10/17
JPMS
03/10/17
NO CHANGE
Target $42
JPMS
Overweight
JPMorgan raises Sarepta price target after payers survey
JPMorgan analyst Anupam Rama raised his price target for Sarepta Therapeutics to $42 from $40 after conducting a "quick" survey of U.S. based payers. The stock closed yesterday down 70c to $32.73. The results indicate broad and early coverage of Sarepta's Duchene Muscular Dystrophy treatment Exondys 51, Rama tells investors in a research note. Further, the survey shows rapid time from patient start form submission to authorized drug reimbursement, and a steady increase in patient adds over the next 12 months, the analyst adds. The results also made clear, however, that increased disease education is needed at the payer level. The analyst is "very encouraged" by the survey results and increased his 2017 Exondys 51 sales estimate to $94M, above the $90M-$91M consensus. He reiterates an Overweight rating on Sarepta.
03/02/17
LEER
03/02/17
UPGRADE
Target $47
LEER
Outperform
Leerink upgrades Sarepta to Outperform with $47 price target
Leerink analyst Joseph Schwartz upgraded Sarepta Therapeutics to Outperform from Market Perform saying the stock now reflects "reasonable expectations" for the Exondys launch. Management's new revenue guidance looks "highly conservative," Schwartz tells investors in a research note. The analyst believes share upside could come from Exondys 51 approval in Europe and/or successful development of follow-on antisense candidates. He raised his price target for Sarepta shares to $47 from $27. The stock closed yesterday down 73c to $30.38.
FOLD Amicus
$7.14

0.07 (0.99%)

11/29/16
COWN
11/29/16
NO CHANGE
Target $12
COWN
Outperform
Amicus price target lowered to $12 from $15 at Cowen
Cowen analyst Ritu Baral lowered her price target on Amicus to $12 from $15 after the FDA told the company it could not file the Galafold NDA with current data and that data from a new trial is expected in 2019. Baral maintained her Outperform rating on Amicus, stating that the planned GI trial has a good chance of success.
01/24/17
BARD
01/24/17
UPGRADE
BARD
Outperform
Amicus upgraded to Outperform from Neutral at Baird
01/24/17
01/24/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tableau (DATA) upgraded to Buy from Neutral at Citi with analyst Walter Pritchard saying consensus estimates for fiscal 2017 look low. Revenue transition impacted numbers more than the Street realized in 2016, Pritchard tells investors in a research note. The analyst raised his price target for the shares to $64 from $50. 2. Agrium (AGU) upgraded to Outperform from Market Perform at Cowen, while CF Industries (CF), Mosaic (MOS), and Potash (POT) were upgraded to Market Perform from Underperform. 3. Calithera Biosciences (CALA) upgraded to Neutral from Sell at Citi with analyst Robyn Karnauskas citing her conversation with management. Management now appears more open to partnering, Karnauskas tells investors in a research note. 4. Home Bancshares (HOMB) upgraded to Buy from Hold at Sandler O'Neill. 5. Amicus (FOLD) upgraded to Outperform from Neutral at Baird with analyst Michael Ulz saying the company removed two overhangs by providing regulatory clarity for Galafold in the U.S. as well as a strengthening its balance sheet. Ulz raised his price target to $10 from $7 on Amicus shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/24/17
BARD
01/24/17
UPGRADE
Target $10
BARD
Outperform
Amicus upgraded to Outperform at Baird
As reported previously, Baird analyst Michael Ulz upgraded Amicus to Outperform from Neutral saying the company removed two overhangs by providing regulatory clarity for Galafold in the U.S. as well as a strengthening its balance sheet. The analyst believes the launch of Galafold by itself supports the company's current valuation and he sees multiple opportunities for upside from its pipeline. Ulz raised his price target to $10 from $7 on Amicus shares.
CATB Catabasis Pharmaceuticals
$1.32

-0.085 (-6.05%)

03/17/17
OPCO
03/17/17
NO CHANGE
Target $11
OPCO
Outperform
Oppenheimer remains bullish on Catabasis Pharmaceuticals
Oppenheimer analyst Hartaj Singh remains bullish on Catabasis Pharmaceuticals after quarterly results. The analyst notes that the company is hvaing an eventful 2017 with edasalonexent not meeting its primary and secondary endpoints in Part B of the MoveDMD clinical trial. However, a potential efficacy signal was noted and the focus on the earnings call was Part C of the MoveDMD trial, he argues, adding that he is "cautiously optimistic" that long-term treatment in Part C may show enough of an efficacy signal for the drug to move forward into further clinical trials. Singh reiterates an Outperform rating and $11 price target on the shares.
02/01/17
OPCO
02/01/17
NO CHANGE
Target $11
OPCO
Outperform
Catabasis Pharmaceuticals price target lowered to $11 from $18 at Oppenheimer
Oppenheimer analyst Hartaj Singh lowered his price target for Catabasis Pharmaceuticals to $11 from $18 after the company announced that Part B of the MoveDMD clinical trial in Duchenne muscular dystrophy did not meet its primary endpoint. The analyst reiterates an Outperform rating on the shares.
02/01/17
COWN
02/01/17
DOWNGRADE
Target $4
COWN
Market Perform
Catabasis Pharmaceuticals downgraded to Market Perform from Outperform at Cowen
Cowen analyst Phil Nadeau downgraded Catabasis Pharmaceuticals to Market Perform from Outperform following the failed trial for its lead candidate for Duchenne muscular dystrophy. It missed its primary endpoint and showed some signs of activity on secondary endpoints, but they were not strong enough to provide confidence the agent could be successfully developed, said Nadeau, who lowered his price target to $4 from $30 on Catabasis shares.
02/01/17
SBSH
02/01/17
DOWNGRADE
Target $1.5
SBSH
Neutral
Catabasis Pharmaceuticals downgraded to Neutral from Buy at Citi
Citi analyst Joel Beatty downgraded Catabasis Pharmaceuticals to Neutral and cut his price target for the shares to $1.50 from $8 following the company's failed Duchenne muscular dystrophy trial.

TODAY'S FREE FLY STORIES

PINC

Premier

$34.21

0.04 (0.12%)

20:14
10/23/17
10/23
20:14
10/23/17
20:14
Downgrade
Premier rating change  »

Premier downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VBTX

Veritex

$26.94

-0.17 (-0.63%)

19:29
10/23/17
10/23
19:29
10/23/17
19:29
Earnings
Veritex reports Q3 core EPS 28c, consensus 30c »

For the three months…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

OIBR

Oi S.A.

19:08
10/23/17
10/23
19:08
10/23/17
19:08
Hot Stocks
Oi: Court postpones general meeting of creditors »

Oi announced that, at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAS

Hasbro

$89.75

-8.44 (-8.60%)

18:24
10/23/17
10/23
18:24
10/23/17
18:24
Hot Stocks
Hasbro CEO: Had a very strong quarter »

Expects to make a revised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

LGF.A

Lionsgate

$29.59

-0.5 (-1.66%)

, LGF.B

Lionsgate

$28.44

-0.6 (-2.07%)

18:07
10/23/17
10/23
18:07
10/23/17
18:07
Hot Stocks
Lionsgate names Rohit Jain to head new office in Mumbai, India »

Lionsgate (LGF.A, LGF.B)…

LGF.A

Lionsgate

$29.59

-0.5 (-1.66%)

LGF.B

Lionsgate

$28.44

-0.6 (-2.07%)

DISH

Dish

$48.98

-0.32 (-0.65%)

VDTH

Videocon d2h

$8.00

-0.22 (-2.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

  • 09

    Nov

ALE

Allete

$78.62

-0.31 (-0.39%)

18:06
10/23/17
10/23
18:06
10/23/17
18:06
Hot Stocks
Wisconsin jury delivers verdict in favor of U.S. Water in Novozymes suit »

U.S. Water, an Allete…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 05

    Nov

SYT

Syngenta

$92.12

0.05 (0.05%)

, ADAM

A.D.A.M.

18:04
10/23/17
10/23
18:04
10/23/17
18:04
Hot Stocks
Syngenta and Adama to sell portfolio of crop products to Nufarm for $490M »

Syngenta (SYT) announced…

SYT

Syngenta

$92.12

0.05 (0.05%)

ADAM

A.D.A.M.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$98.70

-0.7 (-0.70%)

17:54
10/23/17
10/23
17:54
10/23/17
17:54
Periodicals
Disney sees new 'Thor' movie outpacing earlier ones, Bloomberg says »

Disney sees "Thor:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

VIVO

Meridian Bioscience

$15.20

-0.6 (-3.80%)

17:31
10/23/17
10/23
17:31
10/23/17
17:31
Hot Stocks
Meridian Bioscience comments on FDA Warning Letter issued to subsidiary »

Meridian Bioscience…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APRN

Blue Apron

$5.15

0.07 (1.38%)

17:30
10/23/17
10/23
17:30
10/23/17
17:30
Hot Stocks
Blue Apron names Lainie Cooney chief HR officer »

Blue Apron announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

WSFS

WSFS Financial

$50.25

-0.5 (-0.99%)

17:29
10/23/17
10/23
17:29
10/23/17
17:29
Hot Stocks
WSFS Financial raises quarterly dividend 29% to 9c per share »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Nov

  • 15

    Nov

CONN

Conn's

$26.85

-0.75 (-2.72%)

17:28
10/23/17
10/23
17:28
10/23/17
17:28
Hot Stocks
Conn's sees Q3 SSS down 9% to down 5%, provision for bad debts at $56M-$61M »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WSFS

WSFS Financial

$50.25

-0.5 (-0.99%)

17:27
10/23/17
10/23
17:27
10/23/17
17:27
Earnings
WSFS Financial reports Q3 EPS 64c, consensus 65c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Nov

  • 15

    Nov

VBTX

Veritex

$26.94

-0.17 (-0.63%)

17:27
10/23/17
10/23
17:27
10/23/17
17:27
Hot Stocks
Veritex names Michael Bryan chief information officer »

Veritex Holdings, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

TNDM

TNDM

17:25
10/23/17
10/23
17:25
10/23/17
17:25
Hot Stocks
Breaking Hot Stocks news story on TNDM »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

CLB

Core Laboratories

$87.75

-1.74 (-1.94%)

17:21
10/23/17
10/23
17:21
10/23/17
17:21
Hot Stocks
Core Laboratories sees Q4 free cash flow exceeding net income »

Fourth quarter 2017 FCF…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CLB

Core Laboratories

$87.75

-1.74 (-1.94%)

17:20
10/23/17
10/23
17:20
10/23/17
17:20
Earnings
Core Laboratories sees Q4 revenue approximately 58c, consensus 58c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CLB

Core Laboratories

$87.75

-1.74 (-1.94%)

17:18
10/23/17
10/23
17:18
10/23/17
17:18
Earnings
Core Laboratories reports Q3 GAAP EPS 48c, consensus 44c »

Reports Q3 revenue $166M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

LKQ

LKQ Corp.

$37.06

-0.28 (-0.75%)

, DOV

Dover

$95.54

0.59 (0.62%)

17:17
10/23/17
10/23
17:17
10/23/17
17:17
Hot Stocks
LKQ Corp to acquire aftermarket business of Dover subsidiary Warn Industries »

LKQ Corporation (LKQ)…

LKQ

LKQ Corp.

$37.06

-0.28 (-0.75%)

DOV

Dover

$95.54

0.59 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

KNL

Knoll

$20.00

-0.02 (-0.10%)

, HMST

HomeStreet

$28.60

-0.25 (-0.87%)

17:17
10/23/17
10/23
17:17
10/23/17
17:17
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Knoll…

KNL

Knoll

$20.00

-0.02 (-0.10%)

HMST

HomeStreet

$28.60

-0.25 (-0.87%)

CR

Crane

$83.61

-0.5 (-0.59%)

IPXL

Impax

$20.35

-0.9 (-4.24%)

ICPT

Intercept

$65.60

-1.25 (-1.87%)

SWK

Stanley Black & Decker

$158.19

-1.93 (-1.21%)

NKE

Nike

$53.66

0.6 (1.13%)

HNI

HNI Corporation

$42.29

-0.57 (-1.33%)

WHR

Whirlpool

$182.50

0.04 (0.02%)

ZION

Zions Bancorp

$46.39

-0.37 (-0.79%)

JBT

John Bean Technologies

$104.05

0.1 (0.10%)

IMDZ

Immune Design

CRBP

Corbus Pharmaceuticals

$7.40

-0.375 (-4.82%)

QURE

uniQure

$18.52

-0.75 (-3.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 06

    Nov

  • 08

    Nov

  • 09

    Nov

  • 09

    Nov

  • 13

    Nov

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

HBI

Hanesbrands

$22.86

-0.63 (-2.68%)

17:17
10/23/17
10/23
17:17
10/23/17
17:17
Initiation
Hanesbrands initiated at Deutsche Bank »

Hanesbrands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

PVH

PVH Corp.

$129.68

1.37 (1.07%)

17:15
10/23/17
10/23
17:15
10/23/17
17:15
Initiation
PVH Corp. initiated at Deutsche Bank »

PVH Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NYT

New York Times

$19.55

0.1 (0.51%)

17:15
10/23/17
10/23
17:15
10/23/17
17:15
Hot Stocks
Breaking Hot Stocks news story on New York Times »

Darsana Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$1.01

0.01 (1.00%)

17:07
10/23/17
10/23
17:07
10/23/17
17:07
Hot Stocks
U.S. Energy announces participation in upcoming drilling program »

U.S. Energy announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KOS

Kosmos

$7.44

-0.07 (-0.93%)

, HES

Hess Corp.

$45.21

0.18 (0.40%)

17:05
10/23/17
10/23
17:05
10/23/17
17:05
Hot Stocks
Kosmos to acquire interest in exploration licenses in Gulf of Guinea for $650M »

Kosmos Energy announced…

KOS

Kosmos

$7.44

-0.07 (-0.93%)

HES

Hess Corp.

$45.21

0.18 (0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.